Cargando…
Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion
Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g., ischemic/reperfused), but not in the h...
Autores principales: | Brenner, Gábor B., Makkos, András, Nagy, Csilla Terézia, Onódi, Zsófia, Sayour, Nabil V., Gergely, Tamás G., Kiss, Bernadett, Görbe, Anikó, Sághy, Éva, Zádori, Zoltán S., Lázár, Bernadette, Baranyai, Tamás, Varga, Richárd S., Husti, Zoltán, Varró, András, Tóthfalusi, László, Schulz, Rainer, Baczkó, István, Giricz, Zoltán, Ferdinandy, Péter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140447/ https://www.ncbi.nlm.nih.gov/pubmed/32111102 http://dx.doi.org/10.3390/cells9030551 |
Ejemplares similares
-
Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning
por: Baranyai, Tamás, et al.
Publicado: (2015) -
Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo
por: Weber, Bennet Y., et al.
Publicado: (2022) -
Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications
por: Ferdinandy, Péter, et al.
Publicado: (2019) -
Effects of Bempedoic Acid in Acute Myocardial Infarction in Rats: No Cardioprotection and No Hidden Cardiotoxicity
por: Gergely, Tamás G., et al.
Publicado: (2023) -
Somatostatin and Its Receptors in Myocardial Ischemia/Reperfusion Injury and Cardioprotection
por: Vörös, Imre, et al.
Publicado: (2021)